Evidence map›Paper›PMID 39604851›Full record

ArticleBMC genomics2024

Landscape of antisense genes in the human genome and identification of new human hepatic antisense RNAs by long-read sequencing.

Juan Jose Rojo-Carrillo, Pedro Garrido-Rodríguez, Maria Llamas-López, Rosa Cifuentes-Riquelme, Jose Padilla, Bruno Ramos-Molina, Maria Luisa Lozano, Belen de la Morena-Barrio, Maria Eugenia de la Morena-Barrio, Javier Corral

Abstract read
In one paragraph

Article in BMC genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Juan Jose Rojo-Carrillo *Servicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain.
Pedro Garrido-Rodríguez *Servicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain.
Maria Llamas-LópezServicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain.
Rosa Cifuentes-RiquelmeServicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain.
Jose PadillaServicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain.
Bruno Ramos-MolinaGrupo de Obesidad, Diabetes y Metabolismo, Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Murcia, Spain.
Maria Luisa LozanoServicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain.
Belen de la Morena-BarrioServicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain. belendelamorenabarrio@gmail.com.
Maria Eugenia de la Morena-Barrio *Servicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain. uge2985@hotmail.com.
Javier Corral *Servicio de Hematología, Centro Regional de Hemodonación, Hospital General Universitario Morales Messeguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Ronda de Garay s/n, Murcia, 30003, Spain.

Funding

Centro de Investigación Biomédica en red de Enfermedades Raras, Spain CB15/00055Centro de Investigación Biomédica en red de Enfermedades Raras, Spain Predoctoral fellowshipFundación Española de Trombosis y Hemostasia Predoctoral fellowshipInstituto de Salud Carlos III PI21/00174Instituto de Salud Carlos III PMP21/00052Instituto de Salud Carlos III Predoctoral fellowshipMinisterio de Ciencia e Innovación RYC2021-031000-I
6 · The paper itself

Abstract

backgroundProtein-coding genes have been considered the functional part of the genome, although they represent only 2% of the genome. In contrast, more than 90% of the genome produces non-coding RNA (ncRNA), including antisense (AS) genes, a type of long non-coding genes (encoding transcripts > 200 nucleotides) located on the opposite strand of coding genes. Therefore, antisense RNA (asRNA) can be complementary to the counterpart sense RNA, supporting a regulatory role with potential pathogenic consequences, as their deregulation has been associated with cardiovascular disease, cancer, and diabetes.

resultsWe performed an in-depth review of AS genes in Ensembl and evaluated the expression of AS genes in human liver by third-generation RNA sequencing methods. Currently, 1656 AS genes overlapping with 1556 sense genes have been identified in the human genome. Coding genes with antisense counterparts were significantly larger and had higher transcriptional activity than genes without antisense counterparts. RNA nanopore sequencing of 15 human livers identified 185 transcripts (55 novel) from 150 known AS genes, and 1316 transcripts from 807 sense genes, with 111 sense-antisense pairs. Sense transcripts showed higher expression than antisense transcripts. Remarkably, RNA nanopore sequencing of human livers identified 146 transcripts (67 novel) corresponding to 118 possible novel AS genes.

conclusionThis study reveals the landscape of AS genes in the human genome and demonstrates the power of long-read RNA sequencing to identify novel transcripts and even novel AS genes, exploring the relationship between sense and AS gene expression as well.

Indexed as

Genome, HumanLiverRNA, AntisenseHumansNanopore SequencingRNA, Long NoncodingSequence Analysis, RNARNA, AntisenseRNA, Long NoncodingAntisense geneAntisense RNAGenomeLong non-coding RNAsLong-read sequencingTranscriptome

Identifiers

PMID39604851
PMCPMC11603882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.